Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA.
Company profile
Ticker
RARX
Exchange
Website
CEO
Douglas A. Treco
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
RARX stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
13 Apr 20
EFFECT
Notice of effectiveness
9 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Apr 20
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Apr 20
POSASR
Automatic shelf registration (post-effective amendment)
2 Apr 20
POS AM
Prospectus update (post-effective amendment)
2 Apr 20
8-K
UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients
2 Apr 20
Latest ownership filings
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|